Introduction: In human malignancies, cyclin A worse prognosis relates to an overexpression. We examined the relationships between cyclin A immunohistochemistry expression and the clinicopathological features of Wilms tumor (WT), preoperative chemotherapy (PrOpChTh), overall survival (OS), and other factors.
Aim of the study: The objective of this study is to determine the prognosis of Wilms tumor (WT) patients utilizing immunohistochemistry (IHC) of cyclin A.
Subjects and Methods: WT patients who had nephrectomy surgery at a tertiary referral hospital between January 1996 and December 2015 were included in the retrospective study and non-concurrent cohort analysis. Over the 5-year follow-up period, recurrence, and cancer-specific mortality (CSM) were identified as adverse outcomes. The cyclin A IHC procedure employed formalin-fixed, paraffin-embedded WT tissues.
Results: Patients with WTs had 33.4 percent greater cyclin A levels. Blastemal components were much more overexpressed in stage 3 and stage 4 cancers (77.8 percent and 66.7 percent , respectively). Cyclin A was discovered to be overexpressed in 66.7 percent of metastasizing patients but only 33.3 percent of non-metastasizing patients. High recurrence rates were also connected to CSM and cyclin A immunopositivity. Risk factors such as advanced stage, UFH, extracapsular extension, tumour rupture, lymphadenopathy, and venous thrombosis were not associated with a poor prognosis. Patients who have had recurrences have a worse likelihood of survival.
Conclusions: Overexpression of Cyclin A in WT may indicate a bad prognosis. More patients should be included in future study. WT's capacity to spread metastatically was unaffected by cyclin A overexpression.